Epitope Reactions Can Be Gauged by Relative Antibody Discriminating Specificity (RADS) Values Supported by Deletion, Substitution and Cysteine Bridge Formation Analyses: Potential Uses in Pathogenesis Studies

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2012 May 2

PMID 22546090

Citations 2

Authors

Andrew K I Falconar

Affiliations

Soon will be listed here.

Abstract

Background: Epitope-mapping of infectious agents is essential for pathogenesis studies. Since polyclonal antibodies (PAbs) and monoclonal antibodies (MAbs) are always polyspecific and can react with multiple epitopes, it is important to distinguish between specific and non-specific reactions. Relative antibody discriminating specificity (RADS) values, obtained from their relative ELISA reactions with L-amino acid peptides prepared in the natural versus reverse orientations (x-fold absorbance natural/absorbance reverse = RADS value) may be valuable for this purpose.PAbs generated against the dengue type-2 virus (DENV-2) nonstructural-1 (NS1) glycoprotein candidate vaccine also reacted with both DENV envelope (E) glycoproteins and blood-clotting proteins. New xKGSx/xSGKx amino acid motifs were identified on DENV-2 glycoproteins, HIV-1 gp41 and factor IXa. Their potential roles in DENV and HIV-1 antibody-enhanced replication (AER) and auto-immunity were assessed.In this study, a) RADS values were determined for MAbs and PAbs, generated in congeneic (H2: class II) mice against DENV NS1 glycoprotein epitopes, to account for their cross-reaction patterns, and b) MAb 1G5.3 reactions with xKGSx/xSGKx motifs present in the DENV-4 NS1, E and HIV-1 glycoproteins and factor IXa were assessed after the introduction of amino acid substitutions, deletions, or intra-/inter-cysteine (C-C) bridges.

Results: MAbs 1H7.4, 5H4.3, 3D1.4 and 1G5.3 had high (4.23- to 16.83-fold) RADS values against single epitopes on the DENV-2 NS1 glycoprotein, and MAb 3D1.4 defined the DENV complex-conserved LX1 epitope. In contrast, MAbs 1G5.4-A1-C3 and 1C6.3 had low (0.47- to 1.67-fold) RADS values against multiple epitopes. PAb DENV complex-reactions occurred through moderately-high (2.77- and 3.11-fold) RADS values against the LX1 epitope. MAb 1G5.3 reacted with xSGKx motifs present in DENV-4 NS1 and E glycoproteins, HIV-1 gp41 and factor IXa, while natural C-C bridge formations or certain amino acid substitutions increased its binding activity.

Conclusions: These results: i) were readily obtained using a standard 96-well ELISA format, ii) showed the LX1 epitope to be the immuno-dominant DENV complex determinant in the NS1 glycoprotein, iii) supported an antigenic co-evolution of the DENV NS1 and E glycoproteins, and iv) identified methods that made it possible to determine the role of anti-DENV PAb reactions in viral pathogenesis.

Citing Articles

Refining wet lab experiments with in silico searches: A rational quest for diagnostic peptides in visceral leishmaniasis.

Bremer Hinckel B, Marlais T, Airs S, Bhattacharyya T, Imamura H, Dujardin J PLoS Negl Trop Dis. 2019; 13(5):e0007353.

PMID: 31059497 PMC: 6522066. DOI: 10.1371/journal.pntd.0007353.

Development of peptide-based lineage-specific serology for chronic Chagas disease: geographical and clinical distribution of epitope recognition.

Bhattacharyya T, Falconar A, Luquetti A, Costales J, Grijalva M, Lewis M PLoS Negl Trop Dis. 2014; 8(5):e2892.

PMID: 24852444 PMC: 4031129. DOI: 10.1371/journal.pntd.0002892.

References

Fust G . Enhancing antibodies in HIV infection. Parasitology. 1997; 115 Suppl:S127-40. DOI: 10.1017/s0031182097001819. View

Richards F, Konigsberg W, Rosenstein R, VARGA J . On the specificity of antibodies. Science. 1975; 187(4172):130-7. DOI: 10.1126/science.46122. View

Shashidharamurthy R, Zhang F, Amano A, Kamat A, Panchanathan R, Ezekwudo D . Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J Immunol. 2009; 183(12):8216-24. PMC: 2796592. DOI: 10.4049/jimmunol.0902550. View

Falconar A, Martinez F . The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease. PLoS One. 2011; 6(6):e21024. PMC: 3120820. DOI: 10.1371/journal.pone.0021024. View

Goncalvez A, Purcell R, Lai C . Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol. 2004; 78(23):12919-28. PMC: 525008. DOI: 10.1128/JVI.78.23.12919-12928.2004. View

Efroni S, Cohen I . The heuristics of biologic theory: the case of self-nonself discrimination. Cell Immunol. 2003; 223(1):87-9. DOI: 10.1016/s0008-8749(03)00151-5. View

Ray P, Sharma Y . Molecular cloning and serological characterization of a new Plasmodium vivax recombinant antigen which contains apolipoprotein B-100 like sequences. Biochem Biophys Res Commun. 1992; 184(2):668-72. DOI: 10.1016/0006-291x(92)90641-w. View

Oldstone M, Tishon A, Lewicki H, Dyson H, Feher V, Wright P . Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy. J Virol. 1991; 65(4):1727-34. PMC: 239977. DOI: 10.1128/JVI.65.4.1727-1734.1991. View

Edelman G, Gally J . Degeneracy and complexity in biological systems. Proc Natl Acad Sci U S A. 2001; 98(24):13763-8. PMC: 61115. DOI: 10.1073/pnas.231499798. View

10.

Crill W, Chang G . Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004; 78(24):13975-86. PMC: 533943. DOI: 10.1128/JVI.78.24.13975-13986.2004. View

11.

Parnes O . From interception to incorporation: degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology. Mol Immunol. 2004; 40(14-15):985-91. DOI: 10.1016/j.molimm.2003.11.021. View

12.

Liu W, Chen Y . High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol. 2005; 35(2):505-14. DOI: 10.1002/eji.200425749. View

13.

Nimmo G, Lew A, Stanley C, Steward M . Influence of antibody affinity on the performance of different antibody assays. J Immunol Methods. 1984; 72(1):177-87. DOI: 10.1016/0022-1759(84)90446-0. View

14.

Cohn M . Degeneracy, mimicry and crossreactivity in immune recognition. Mol Immunol. 2004; 42(5):651-5. DOI: 10.1016/j.molimm.2004.09.010. View

15.

Halstead S, Mahalingam S, Marovich M, Ubol S, Mosser D . Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010; 10(10):712-22. PMC: 3057165. DOI: 10.1016/S1473-3099(10)70166-3. View

16.

Bessoff K, Delorey M, Sun W, Hunsperger E . Comparison of two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. Clin Vaccine Immunol. 2008; 15(10):1513-8. PMC: 2565928. DOI: 10.1128/CVI.00140-08. View

17.

Wang J, Tan W, Chen Y, Lu X, Lu Y, Qin S . Full-length cDNA cloning and protein three-dimensional structure modeling of factor VII of rhesus monkey, Macaca mulatta. Blood Cells Mol Dis. 2007; 40(2):237-43. DOI: 10.1016/j.bcmd.2007.08.003. View

18.

Murphy B, Whitehead S . Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011; 29:587-619. DOI: 10.1146/annurev-immunol-031210-101315. View

19.

Halstead S . Dengue. Lancet. 2007; 370(9599):1644-52. DOI: 10.1016/S0140-6736(07)61687-0. View

20.

Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen Y . High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine. 2004; 23(3):366-71. DOI: 10.1016/j.vaccine.2004.05.028. View